ResearchMoz added Latest Research Report titled " Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth " to it's Large Report database.
Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=536322
However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.
Scope
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
What factors are driving the market growth?
How can the factors limiting growth be overcome?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=536322
However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.
Scope
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
What factors are driving the market growth?
How can the factors limiting growth be overcome?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 8
2.1 Therapy Area Introduction 8
2.2 Symptoms 8
2.3 Etiology and Pathophysiology 9
2.4 Co-morbidities and Complications 11
2.5 Epidemiology Patterns and Forecasts – Prevalence, Patient Segmentation, Diagnostic and Treatment Usage Rates 11
2.5.1 Rheumatoid Arthritis 12
2.5.2 Psoriasis 13
2.5.3 Systemic Lupus Erythematosus 14
2.6 Treatment 15
2.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs 16
2.6.2 Glucocorticoids 17
2.6.3 Biologics 17
3 Key Marketed Products 19
3.1 Overview 19
3.2 Humira (adalimumab) 21
3.3 Remicade (infliximab) 22
3.4 Enbrel (etanercept) 24
3.5 Rituxan (rituximab) 26
3.6 Stelara (ustekinumab) 27
3.7 Prograf (tacrolimus) 28
3.8 Cimzia (certolizumab pegol) 30
3.9 Simponi (golimumab) 31
3.10 Conclusion 33
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment